Circadian rhythms and cancer chemotherapy

被引:28
作者
Wood, PA
Hrushesky, WJM
机构
[1] STRATTON VET AFFAIRS MED CTR, ALBANY, NY 12208 USA
[2] ALBANY MED COLL, ALBANY, NY 12208 USA
来源
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION | 1996年 / 6卷 / 04期
关键词
circadian; cancer chemotherapy; therapeutic index; biochemical pharmacology; cytokinetics; drug delivery; cytokines and growth factors;
D O I
10.1615/CritRevEukarGeneExpr.v6.i4.10
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Temporal coordination of biologic processes with an approximately 24-h cycle (circadian) is common throughout the animal and plant kingdom and even in some prokaryotic organisms. In all organisms studied, the capability to keep biologic time is an inherited characteristic located intracellularly. These biological clocks anticipate and get the organism ready for regular environmental changes. This indicates both the ubiquity and the weight of the selective environmental pressure to keep time accurately. Several molecular strategies for biologic time keeping have apparently arisen independently several times throughout evolution. The anatomic, biochemical, and molecular mechanisms of the clock are in the process of being defined. This temporal organization at the cellular, organ, and organismic levels results in predictable differences in the capacity of plants, animals, and human beings to respond to therapeutic interventions administered at different times throughout important biologic cycles (e.g., circadian timed therapy). In the treatment of the cancer bearing host, circadian timing of surgery, anticancer drugs, radiation therapy, and biologic agents can result in improved toxicity profiles, enhanced tumor control, and improved host survival. The routine clinical application of such principles is facilitated by the availability of programmable drug delivery devices. Rhythm frequency ranges other than 24-h (e.g., low frequency: menstrual; high frequency: 10 to 120 min) may also be important to understanding health and disease and to designing successful therapy in diseases as diverse as cancer, infertility, and diabetes.
引用
收藏
页码:299 / 343
页数:45
相关论文
共 298 条
[1]  
ABO T, 1981, J IMMUNOL, V126, P1360
[2]  
ABRAMS PG, 1985, NEW ENGL J MED, V312, P443
[3]  
Allegra C J, 1990, Cancer Chemother Biol Response Modif, V11, P1
[4]  
ALLEGRINI G, 1995, BIOL RHYTHM RES, V26, P361
[5]  
ANDERSON N, 1989, CANCER, V63, P233, DOI 10.1002/1097-0142(19890115)63:2<233::AID-CNCR2820630205>3.0.CO
[6]  
2-E
[7]  
ANDRADE JD, 1986, ADV POLYM SCI, V79, P1
[8]  
[Anonymous], INT J CHRONOBIOL
[9]  
[Anonymous], 1992, BIOL RHYTHMS CLIN LA
[10]  
[Anonymous], ANN ONCOLOGY S8